MALE GENDER IS ASSOCIATED WITH AN IMPAIRED OVERALL AND PROGRESSION FREE SURVIVAL IN PATIENTS WITH PROGNOSTIC LOW RISK CHRONIC LYMPHOCYTIC LEUKEMIA
(Abstract release date: 05/19/16)
EHA Library. da Cunha-Bang C. 06/09/16; 132630; E1081
Disclosure(s): Geisler: GlaxoSmithKline: Consultancy; Novartis: Consultancy; Janssen: Consultancy; Celgene: Consultancy; Gilead: Consultancy; Roche: Consultancy.
Niemann: Novartis: Travel grant; Janssen: Consultancy; Roche: Consultancy; Gilead: Consultancy.
Dr. Caspar da Cunha-Bang
Contributions
Contributions
Abstract
Abstract: E1081
Type: Eposter Presentation
Background
Recently the new International Prognostic Index for Chronic Lymphocytic Leukemia (CLL) patients (CLL-IPI) was developed (Bahlo J, et al: The International Prognostic Index For Patients With Chronic Lymphocytic Leukaemia (CLL-IPI). ICML, Lugano, 2015). The index does not include gender as a weighted factor. However, previous analyses of Danish CLL patients indicate gender specific variations in Overall Survival (da Cunha-Bang C, et al: Improved Survival for Patients with CLL in the Era of Combination Chemoimmunotherapy - a Danish Population Based Study. Blood 126:1740-1740, 2015).
Aims
To analyze gender-specific outcome for patients following diagnosis with CLL for different CLL-IPI risk groups based on the Danish CLL-database.
Methods
All patients diagnosed with CLL in Denmark were registered and prospectively followed in the Danish National CLL database (2008-2015). The present analysis included all patients for whom all five factors included in the CLL-IPI score were registered (del(17p/TP53, IGHV mutation status, beta-2-microglobulin, Binet/Rai stage, age). Overall survival (OS), treatment free survival (TFS) and progression free survival (PFS) were calculated using Kaplan Meier and multivariate Cox regression models adjusted for relevant confounders.
Results
In total, 1541 patients were included. Analyzing the entire population, no difference in OS was found based on gender. However, analysis of the 1314 (778 (59%) male, 536 (41%) female) patients from the low and intermediate risk CLL-IPI score groups showed an impaired OS ((Hazard ratio (HR (95%CI)) for death; 1.7 (1.2 – 2.3) P = 0.002)) for male versus female patients. No variation in TFS was found. However, following treatment male patients had a significantly impaired PFS (HR for progression; 3.0 (1.5 – 6.2) P = 0.003)) versus female patients.
Conclusion
Male CLL patients in low and intermediate CLL-IPI risk groups have a higher risk of dying than their female counterparts. The increased risk of dying from non-CLL related causes for male patients may explain this difference, which is overruled by the increased risk of dying from CLL among high and very high CLL-IPI risk groups. Following CLL treatment the gender disadvantage is apparently accentuated. Focus on reducing pre-treatment risk factors for male CLL patients may improve survival in this population. Further analyses of cause of death following treatment in male CLL patients are warranted.
Session topic: E-poster
Keyword(s): Chronic lymphocytic leukemia, Gender, Survival
Type: Eposter Presentation
Background
Recently the new International Prognostic Index for Chronic Lymphocytic Leukemia (CLL) patients (CLL-IPI) was developed (Bahlo J, et al: The International Prognostic Index For Patients With Chronic Lymphocytic Leukaemia (CLL-IPI). ICML, Lugano, 2015). The index does not include gender as a weighted factor. However, previous analyses of Danish CLL patients indicate gender specific variations in Overall Survival (da Cunha-Bang C, et al: Improved Survival for Patients with CLL in the Era of Combination Chemoimmunotherapy - a Danish Population Based Study. Blood 126:1740-1740, 2015).
Aims
To analyze gender-specific outcome for patients following diagnosis with CLL for different CLL-IPI risk groups based on the Danish CLL-database.
Methods
All patients diagnosed with CLL in Denmark were registered and prospectively followed in the Danish National CLL database (2008-2015). The present analysis included all patients for whom all five factors included in the CLL-IPI score were registered (del(17p/TP53, IGHV mutation status, beta-2-microglobulin, Binet/Rai stage, age). Overall survival (OS), treatment free survival (TFS) and progression free survival (PFS) were calculated using Kaplan Meier and multivariate Cox regression models adjusted for relevant confounders.
Results
In total, 1541 patients were included. Analyzing the entire population, no difference in OS was found based on gender. However, analysis of the 1314 (778 (59%) male, 536 (41%) female) patients from the low and intermediate risk CLL-IPI score groups showed an impaired OS ((Hazard ratio (HR (95%CI)) for death; 1.7 (1.2 – 2.3) P = 0.002)) for male versus female patients. No variation in TFS was found. However, following treatment male patients had a significantly impaired PFS (HR for progression; 3.0 (1.5 – 6.2) P = 0.003)) versus female patients.
Conclusion
Male CLL patients in low and intermediate CLL-IPI risk groups have a higher risk of dying than their female counterparts. The increased risk of dying from non-CLL related causes for male patients may explain this difference, which is overruled by the increased risk of dying from CLL among high and very high CLL-IPI risk groups. Following CLL treatment the gender disadvantage is apparently accentuated. Focus on reducing pre-treatment risk factors for male CLL patients may improve survival in this population. Further analyses of cause of death following treatment in male CLL patients are warranted.
Session topic: E-poster
Keyword(s): Chronic lymphocytic leukemia, Gender, Survival
Abstract: E1081
Type: Eposter Presentation
Background
Recently the new International Prognostic Index for Chronic Lymphocytic Leukemia (CLL) patients (CLL-IPI) was developed (Bahlo J, et al: The International Prognostic Index For Patients With Chronic Lymphocytic Leukaemia (CLL-IPI). ICML, Lugano, 2015). The index does not include gender as a weighted factor. However, previous analyses of Danish CLL patients indicate gender specific variations in Overall Survival (da Cunha-Bang C, et al: Improved Survival for Patients with CLL in the Era of Combination Chemoimmunotherapy - a Danish Population Based Study. Blood 126:1740-1740, 2015).
Aims
To analyze gender-specific outcome for patients following diagnosis with CLL for different CLL-IPI risk groups based on the Danish CLL-database.
Methods
All patients diagnosed with CLL in Denmark were registered and prospectively followed in the Danish National CLL database (2008-2015). The present analysis included all patients for whom all five factors included in the CLL-IPI score were registered (del(17p/TP53, IGHV mutation status, beta-2-microglobulin, Binet/Rai stage, age). Overall survival (OS), treatment free survival (TFS) and progression free survival (PFS) were calculated using Kaplan Meier and multivariate Cox regression models adjusted for relevant confounders.
Results
In total, 1541 patients were included. Analyzing the entire population, no difference in OS was found based on gender. However, analysis of the 1314 (778 (59%) male, 536 (41%) female) patients from the low and intermediate risk CLL-IPI score groups showed an impaired OS ((Hazard ratio (HR (95%CI)) for death; 1.7 (1.2 – 2.3) P = 0.002)) for male versus female patients. No variation in TFS was found. However, following treatment male patients had a significantly impaired PFS (HR for progression; 3.0 (1.5 – 6.2) P = 0.003)) versus female patients.
Conclusion
Male CLL patients in low and intermediate CLL-IPI risk groups have a higher risk of dying than their female counterparts. The increased risk of dying from non-CLL related causes for male patients may explain this difference, which is overruled by the increased risk of dying from CLL among high and very high CLL-IPI risk groups. Following CLL treatment the gender disadvantage is apparently accentuated. Focus on reducing pre-treatment risk factors for male CLL patients may improve survival in this population. Further analyses of cause of death following treatment in male CLL patients are warranted.
Session topic: E-poster
Keyword(s): Chronic lymphocytic leukemia, Gender, Survival
Type: Eposter Presentation
Background
Recently the new International Prognostic Index for Chronic Lymphocytic Leukemia (CLL) patients (CLL-IPI) was developed (Bahlo J, et al: The International Prognostic Index For Patients With Chronic Lymphocytic Leukaemia (CLL-IPI). ICML, Lugano, 2015). The index does not include gender as a weighted factor. However, previous analyses of Danish CLL patients indicate gender specific variations in Overall Survival (da Cunha-Bang C, et al: Improved Survival for Patients with CLL in the Era of Combination Chemoimmunotherapy - a Danish Population Based Study. Blood 126:1740-1740, 2015).
Aims
To analyze gender-specific outcome for patients following diagnosis with CLL for different CLL-IPI risk groups based on the Danish CLL-database.
Methods
All patients diagnosed with CLL in Denmark were registered and prospectively followed in the Danish National CLL database (2008-2015). The present analysis included all patients for whom all five factors included in the CLL-IPI score were registered (del(17p/TP53, IGHV mutation status, beta-2-microglobulin, Binet/Rai stage, age). Overall survival (OS), treatment free survival (TFS) and progression free survival (PFS) were calculated using Kaplan Meier and multivariate Cox regression models adjusted for relevant confounders.
Results
In total, 1541 patients were included. Analyzing the entire population, no difference in OS was found based on gender. However, analysis of the 1314 (778 (59%) male, 536 (41%) female) patients from the low and intermediate risk CLL-IPI score groups showed an impaired OS ((Hazard ratio (HR (95%CI)) for death; 1.7 (1.2 – 2.3) P = 0.002)) for male versus female patients. No variation in TFS was found. However, following treatment male patients had a significantly impaired PFS (HR for progression; 3.0 (1.5 – 6.2) P = 0.003)) versus female patients.
Conclusion
Male CLL patients in low and intermediate CLL-IPI risk groups have a higher risk of dying than their female counterparts. The increased risk of dying from non-CLL related causes for male patients may explain this difference, which is overruled by the increased risk of dying from CLL among high and very high CLL-IPI risk groups. Following CLL treatment the gender disadvantage is apparently accentuated. Focus on reducing pre-treatment risk factors for male CLL patients may improve survival in this population. Further analyses of cause of death following treatment in male CLL patients are warranted.
Session topic: E-poster
Keyword(s): Chronic lymphocytic leukemia, Gender, Survival
{{ help_message }}
{{filter}}